Since the last World Symposium on Pulmonary Hypertension in 2008, we have witnessed
numerous and exciting developments in chronic thromboembolic pulmonary hypertension (…

Pulmonary arterial hypertension is a severe disease that has been ignored for a long time.
However, over the past 20 yrs chest physicians, cardiologists and thoracic surgeons have …

… Dartevelle reports no conflicts of interest. Dr. Frost has received research grants from
Actelion, Gilead, Eli Lilly, Pfizer, and United Therapeutics, and honoraria for speaking and/or …

Level of Evidence A Data derived from multiple randomised clinical trials or meta-analyses
Level of Evidence B Data derived from a single randomised clinical trial or large non-…

Background— Chronic thromboembolic pulmonary hypertension, a rare complication of acute
pulmonary embolism, is characterized by fibrothrombotic obstructions of large pulmonary …

… with untreated patients (876 vs 699 dyn.s.cm −5 , P = .0005) (adjustment for cofactors was
not performed). … P. Dartevelle has nothing to disclose with regard to commercial support. …

… P values less than 0.05 were considered statistically significant… P < 0.05, **P < 0.01 as
compared with values for cells from … P < 0.05 and **P < 0.01 as compared with values for cells from …

Thymus-derived CD4 + CD25 + regulatory T (Treg) cells are essential for the maintenance
of immunologic self-tolerance. Despite their critical role in the active suppression of …

… Dartevelle has made a significant contribution in the treatment of locally advanced bron…
Dartevelle No patient had clinical evidence of mediastinallymph node involvement at the time of …

… for a lower body mass index (p < 0.02) in patients with PVOD… p < 0.01). Hemodynamic
parameters showed a lower mean systemic arterial pressure (p < 0.01) and right atrial pressure (p …